Development
Biogen Inc.
BIIB
$138.60
$3.662.71%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 1.16B | 1.46B | 2.66B | 3.13B | 3.05B |
| Total Depreciation and Amortization | 494.80M | 474.50M | 470.20M | 487.60M | 518.40M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 540.00M | 411.50M | -401.30M | -1.65B | -1.29B |
| Change in Net Operating Assets | -648.70M | -988.10M | -1.31B | -293.90M | -890.30M |
| Cash from Operations | 1.55B | 1.36B | 1.43B | 1.68B | 1.38B |
| Capital Expenditure | -277.00M | -298.20M | -283.10M | -249.00M | -240.30M |
| Sale of Property, Plant, and Equipment | -- | 0.00 | 582.60M | 582.60M | 582.60M |
| Cash Acquisitions | -6.93B | -6.34B | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 3.10B | 3.04B | -474.90M | 938.00M | 1.23B |
| Cash from Investing | -4.10B | -3.59B | -175.40M | 1.27B | 1.58B |
| Total Debt Issued | 997.20M | 997.20M | -- | -- | -- |
| Total Debt Repaid | -809.90M | -159.90M | -1.00B | -1.00B | -1.00B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | 0.00 | -250.00M | -750.00M | -750.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -38.00M | -49.30M | -60.30M | -22.00M | 4.90M |
| Cash from Financing | 149.30M | 788.00M | -1.31B | -1.77B | -1.75B |
| Foreign Exchange rate Adjustments | 35.10M | 54.40M | 30.80M | -26.30M | -55.70M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.37B | -1.39B | -28.80M | 1.15B | 1.16B |